Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute discusses the impact of his study on clinical practice and future clinical research. He talks of his hopes for the increase in testing for the mutation and in utilization of MET inhibitors to patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Impact of MET Inhibitors on Future Clinical Practice and Research
